OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: McGill University

3 Projects | 3 Researchers | $1,685,078 Invested

2021

McGill University

Simon Ducharme, MD, MSc, FRCPC

Open-label Clinical Trial of Nabilone for Neuropsychiatric Symptoms in Frontotemporal Dementia

  • Funding Amount: $1,399,078
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active

2007

McGill University

A. Claudio Cuello, OC, MD, DSc, FRSC, FMedSci

A novel combined experimental therapy in an Alzheimer's transgenic model

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

1999

McGill University

Barbara Sherwin, PhD

Effects of Estradiol on Cognitive Function in Elderly Men with Mild Cognitive Impairment

  • Funding Amount: $186,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed